[1]刘 瑜,王 星,代 萌,等.2型糖尿病合并非酒精性脂肪肝的危险因素研究[J].医学信息,2018,31(23):108-110.[doi:10.3969/j.issn.1006-1959.2018.23.029]
　LIU Yu,WANG Xing,DAI Meng,et al.Study on Risk Factors of Type 2 Diabetes Mellitus with Non-alcoholic Fatty liver Disease[J].Journal of Medical Information,2018,31(23):108-110.[doi:10.3969/j.issn.1006-1959.2018.23.029]
点击复制

2型糖尿病合并非酒精性脂肪肝的危险因素研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年23期
页码:
108-110
栏目:
论著
出版日期:
2018-12-01

文章信息/Info

Title:
Study on Risk Factors of Type 2 Diabetes Mellitus with Non-alcoholic Fatty liver Disease
文章编号:
1006-1959（2018）23-0108-03
作者:
刘 瑜; 王 星; 代 萌; 宋金辉
江苏省南京市栖霞区妇幼保健院内科，江苏 南京 210028
Author(s):
LIU Yu; WANG Xing; DAI Meng; SONG Jin-hui
Department of Internal medicine,Qixia District Maternal and Child Health Hospital,Nanjing 210028,Jiangsu,China
关键词:
2型糖尿病; 非酒精性脂肪肝; 危险因素; 甘油三酯; 高密度脂蛋白; 低密度脂蛋白
Keywords:
Type 2 diabetes mellitus; Non-alcoholic fatty liver; Risk factors; Triglyceride; High-density lipoprotein; Low-density lipoprotein
分类号:
R587.1；R575.5
DOI:
10.3969/j.issn.1006-1959.2018.23.029
文献标志码:
A
摘要:
探讨2型糖尿病合并非酒精性脂肪肝的危险因素。方法 选择2017年1月~12月在我院住院的T2DM患者138例，根据是否合并NAFLD分为两组，合并NAFLD的86例患者设为观察组，52例单纯T2DM设为对照组。比较两组一般临床资料及生化指标，采用回归分析判定其中的独立相关的主要危险因素和（或）保护性因素。结果 两组患者BMI、收缩压、糖化血红蛋白、甘油三酯、高密度脂蛋白、低密度脂蛋白、尿酸、同型半胱氨酸、胰岛素抵抗指数等指标比较，差异有统计学意义（P≤0.05）；将上述有差异指标进行二元Logistic回归分析发现，BMI、TG、SUA、HbA1c、HOMA-IR与T2DM合并NAFLD呈正相关（OR＞1，P＜0.05），HDL-C与T2DM合并NAFLD呈负相关（OR＜1，P≤0.05）。结论 T2DM合并NAFLD相当常见，BMI、HOMA-IR、HbA1c、TG、SUA是其危险因素，HDL-C 是其保护因素。胰岛素抵抗在并发NAFLD的T2DM者中更加明显。
Abstract:
Objective To investigate the risk factors of type 2 diabetes mellitus with non-alcoholic fatty liver disease.Methods 138 T2DM patients in our hospital from January to December 2017 were selected and divided into two groups, depending on whether the NAFLD is combined,86 patients combined with NAFLD were treated as observation group and 52 patients with T2DM as control group.Two groups of general clinical data and biochemical indicators were compared, and the main independent risk factors and / or protective factors were determined by regression analysis.Results BMI, systolic blood pressure, glycosylated hemoglobin, triglyceride, high density lipoprotein, low density lipoprotein, uric acid, homocysteine and insulin resistance index were compared between the two groups,the difference was statistically significant (P≤0.05).The results of binary Logistic regression analysis showed that there was a positive correlation between BMI,TG,SUA,HbA1c,HOMA-IR and T2DM combined with NAFLD (OR>1, P<0.05).There was a negative correlation between HDL-C and T2DM combined with NAFLD (OR<1,P≤0.05).Conclusion T2DM combined with NAFLD is common and BMI,HOMA-IR,HbA1c,TG,SUA is the risk factor.HDL-C is the protective factor.Insulin resistance was more pronounced in T2DM patients combined with NAFLD.

参考文献/References:

[1]Paola Portillo-Sanchez,Kenneth Cusi.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes[J].Clinical Diabetes and Endocrinology,2016(2):9.
[2]Targher G,Byrne CD.Non-alcoholic fatty liver disease：an emerging driving force in chronic kidney disease[J].Nat Rev Nephrol,2017,2(20):263-269.
[3]Yabiku K,Mutoh A,Miyagi K,et al.Effects of oral antidiabetic drugs on changes in the liver-to-spleen ratio on computerd tomograghy and inflammatory biomarkers in patients with type 2 diabetes and nonalcoholic fatty liver disease[J].Clin Ther,2017,2(6):5715-5719.
[4]William T,Cefalu MD.Standards of medical care in diadetes-2017[J].Diabetes Care January,2017(40):1.
[5]Chalasani N,Younossi Z,Lavine JE,et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology,2012,55(6):2005-2023.
[6]Singal AG,Manjunath H,Yopp AC,et al.The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis[J].Am J Gastroenterol,2014,109(3):325-334.
[7]Bril F,Cusi K. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action[J].Diabetes Care,2017,40(3):419-430.
[8]Inzucchi SE,Bergenstal RM,Buse JB.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach.Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetologia,2015(58):429-442.
[9]Siddiqui MS,Fuchs M,Idowu MO,et al.Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile[J].Clin Gastroenterol Hepatol,2015(13):1000-1008.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(23):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(23):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(23):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(23):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]谢雨萌,毛乾国.非酒精性脂肪肝患者中医体质及相关证型研究[J].医学信息,2018,31(07):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
　XIE Yu-meng,MAO Qian-guo.Study on TCM Constitution and Correlative Syndromes of Nonalcoholic Fatty Liver Patients[J].Journal of Medical Information,2018,31(23):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
[6]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(23):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[7]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
　GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(23):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[8]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(23):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[9]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
　YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Journal of Medical Information,2022,35(23):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[10]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
　ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Journal of Medical Information,2022,35(23):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]

更新日期/Last Update: 2018-12-17